دراسة بوميديمستات (IMG-7289/MK-3543) مقارنة بأفضل علاج متاح (BAT) لدى المشاركين الذين يعانون من كثرة الصفيحات الأساسية واستجابة غير كافية أو عدم تحمل للهيدروكسي يوريا (MK-3543-006)
This study is testing a new medicine called bomedemstat for a blood condition known as essential thrombocythemia, or ET. ET causes your body to make too many platelets, which are tiny cells that help blood clot. The study is for people who have ET and whose usual medicine, hydroxyurea, isn't helping enough or is causing difficult side effects. We want to find out if bomedemstat is more effective and safer than other available treatments like Anagrelide, Busulfan, Interferon alfa, or Ruxolitinib. By comparing these treatments, the researchers hope to offer better options for managing this condition. The main goal is to see if bomedemstat can lead to a lasting improvement in symptoms and blood counts.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about a blood condition called essential thrombocythemia, often shortened to ET. In ET, your body produces too many small blood cells called platelets. While platelets are important for stopping bleeding, having too many can sometimes lead to serious problems like blood clots or, less commonly, bleeding issues. Many people with ET take a medicine called hydroxyurea to help control their platelet levels.
However, for some people, hydroxyurea either stops working well or causes side effects that are difficult to manage. This study is for those individuals. Researchers want to compare a new medicine, bomedemstat, with other established treatments already used for ET, such as Anagrelide, Busulfan, Interferon alfa, or Ruxolitinib. They want to find out if bomedemstat is a better option for people whose previous treatment isn't quite right.
The main aim is to see if bomedemstat can provide a more lasting and effective control of platelet counts and other symptoms of ET, compared to what is currently available. This is a "Phase 3" study, which means it's one of the final steps in testing a new medicine before it can potentially be made widely available. It's a large study designed to confirm the safety and benefits of bomedemstat.
النقاط الرئيسية
- Tests a new medicine (bomedemstat) for essential thrombocythemia (ET).
- For ET patients whose current treatment (hydroxyurea) isn't working or causing problems.
- Compares bomedemstat to other standard ET treatments.
- Aims to find a more lasting and effective way to manage ET.
- Requires regular hospital visits and monitoring.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
To join this study, you must be an adult aged 18 or over and have been diagnosed with essential thrombocythemia (ET) by an expert. You would also need to have received hydroxyurea for your ET in the past, but it either didn't work well enough, or you couldn't tolerate its side effects.
Your bone marrow, which is where blood cells are made, should show only minor changes related to ET. Your platelet count must also be above 450 (x 10^9/L) just before starting the study medicine. You also need to have a certain level of white blood cells (specifically, neutrophils) of at least 0.75 (x 10^9/L).
There are also some reasons why you might not be able to join. For example, if you've had a bad allergic reaction to medicines similar to bomedemstat or to any of the other treatments being compared. If you have stomach or gut problems that might stop the medicine from being absorbed properly, or if you have a high risk of bleeding, you might not be eligible. If you've had certain types of cancer in the last two years, this might also prevent you from joining, though some very common and easily treated skin cancers (like basal cell carcinoma) wouldn't stop you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have a diagnosis of essential thrombocythemia (ET)?
- Has hydroxyurea stopped working well for your ET, or did you have bad side effects from it?
- Is your platelet count currently high (above 450)?
- Do you have good general health, without severe gut issues or high bleeding risk?
ماذا يتضمن المشاركة؟
If you join this study, you’ll receive either the new medicine, bomedemstat, or one of the existing best available treatments for ET. Your treatment will be decided by chance, like flipping a coin. You'll have regular hospital visits for check-ups, blood tests, and to discuss any side effects you might be experiencing. These visits will help the doctors monitor your health and how the treatment is working. The study is designed to measure how safe and effective the treatments are over time. The exact number and frequency of visits, as well as the total length of your participation, will be explained in detail by the study team. You'll be given all the study medication as part of your participation.
المخاطر والفوائد المحتملة
Locations (161)
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)الرمز البريدي المؤكدغلينديل، الولايات المتحدة
- Los Angeles Cancer Network ( Site 3491)الرمز البريدي المؤكدغلينديل، الولايات المتحدة
- Stanford Cancer Institute ( Site 0107)الرمز البريدي المؤكدستانفورد، الولايات المتحدة
- The Lundquist Institute ( Site 3423)الرمز البريدي المؤكدتورانس، الولايات المتحدة
- University of Colorado Anschutz Medical Campus ( Site 3425)الرمز البريدي المؤكدأورورا، الولايات المتحدة
- Tufts Medical Center ( Site 3408)الرمز البريدي المؤكدبوسطن، الولايات المتحدة
- University of Michigan ( Site 0008)الرمز البريدي المؤكدآن آربر، الولايات المتحدة
- Henry Ford Hospital ( Site 3413)الرمز البريدي المؤكدديترويت، الولايات المتحدة
- Optum Care Cancer Center ( Site 3497)الرمز البريدي المؤكدلاس فيغاس، الولايات المتحدة
- Roswell Park Cancer Institute ( Site 3421)الرمز البريدي المؤكدبوفالو، الولايات المتحدة
- Duke University Health System (DUHS) ( Site 0016)الرمز البريدي المؤكددرهام، الولايات المتحدة
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)الرمز البريدي المؤكدوينستون-سالم، الولايات المتحدة
أسئلة شائعة
What is essential thrombocythemia (ET)?
ET is a condition where your body makes too many platelets, which are blood cells that help with clotting. This can sometimes lead to blood clots or bleeding issues.
What is bomedemstat?
Bomedemstat is a new medicine being tested in this study for people with ET who haven't responded well to standard treatments or experienced side effects.
Will I definitely receive bomedemstat if I join?
Not necessarily. Participants will be randomly assigned to receive either bomedemstat or one of the established treatments currently used for ET.
What kind of commitment is joining the study?
You'll have regular hospital visits for check-ups, blood tests, and to get your study medication. The study team will explain the full schedule.
هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟
Yes, you have the right to leave the study at any time, for any reason, and it won't affect your ongoing medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.